1-14 of 14
Yuko Tanaka, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Pivotal Role of Nicotinamide Phosphoribosyl Transferase in Chronic Myeloid Leukemia Cells Under Hypoxic Condition

Seiichi Okabe, Yuko Tanaka, MD PhD, Akihiko Gotoh, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
https://doi.org/10.1182/blood-2020-140202
Published: 2020
Journal Articles

Targeting Glycolysis in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant in Hypoxic Conditions

Seiichi Okabe, MD PhD, Yuko Tanaka, MD PhD, Mitsuru Moriyama, Akihiko Gotoh, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4344.
https://doi.org/10.1182/blood-2019-129818
Published: 2019
Journal Articles

The Role of Hypoxia on ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Seiichi Okabe, MD PhD, Yuko Tanaka, MD PhD, Mitsuru Moriyama, Akihiko Gotoh, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5369.
https://doi.org/10.1182/blood-2019-129768
Published: 2019
Journal Articles

Peroxisome Proliferator-Activated Receptors: Targets for the Treatment of Philadelphia Chromosome-Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5241.
https://doi.org/10.1182/blood.V130.Suppl_1.5241.5241
Published: 2017
Journal Articles

Aurora A Kinase As a Promising Therapeutic Target in Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3828.
https://doi.org/10.1182/blood.V130.Suppl_1.3828.3828
Published: 2017
Journal Articles

ABL001 with Catalytic-Site Inhibitors Limit the CML Immature Cell Population: Re-Differentiation of CML-iPSCs Study

Tetsuzo Tauchi, MD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1582.
https://doi.org/10.1182/blood.V130.Suppl_1.1582.1582
Published: 2017
Journal Articles

Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC)

Tetsuzo Tauchi, MD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1249.
https://doi.org/10.1182/blood.V130.Suppl_1.1249.1249
Published: 2017
Journal Articles

Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD
Journal: Blood
Blood (2016) 128 (22): 5428.
https://doi.org/10.1182/blood.V128.22.5428.5428
Published: 2016
Journal Articles

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Seiichiro Katagiri, MD PhD, Tetsuzo Tauchi, MD PhD, Yuu Saito, MD, Tamiko Sugro, MD, Michiyo Asano, MD, Seiichiro Yoshizawa, MD PhD, Juri Sakuta, MD PhD, Daigo Akahane, MD PhD, Yuko Tanaka, MD PhD, Nahoko Furuya, MD PhD, Keiko Ando, MD PhD, Hiroaki Fujimoto, MD, Seiichi Okabe, MD PhD, Moritaka Gotoh, MD PhD, Yoshikazu Ito, MD PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD PhD, Kazuma Ohyashiki, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1797.
https://doi.org/10.1182/blood.V124.21.1797.1797
Published: 2014
Journal Articles

Therapeutic Potential Of Targeting Sphingosine-1-Phosuphate and Sphingosine Kinases In Multiple Myeloma

Yuko Tanaka, MD, Seiichi Okabe, MD, Tetsuzo Tauchi, MD, Yoshikazu Ito, MD, PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD, PhD, Kazuma Ohyashiki, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1894.
https://doi.org/10.1182/blood.V122.21.1894.1894
Published: 2013
Journal Articles

Efficacy Of The Polo-Like Kinase Inhibitor, Rigosertib Alone Or In Combination With ABL Tyrosine Kinase Inhibitor Against BCR-ABL-Positive Leukemia Cells

Seiichi Okabe, MD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD, Toshihiko Kitahara, MD, Kazuma Ohyashiki, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3985.
https://doi.org/10.1182/blood.V122.21.3985.3985
Published: 2013
Journal Articles

Activity Of Omacetaxine Mepesuccinate Against Ponatinib Resistant Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD, Seiichiro Katagiri, MD, Toshihiko Kitahara, MD, Kazuma Ohyashiki, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3840.
https://doi.org/10.1182/blood.V122.21.3840.3840
Published: 2013
Journal Articles

Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, M.D., Seiichiro Katagiri, MD, Yuko Tanaka, MD, Kazuma Ohyashiki, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1333.
https://doi.org/10.1182/blood.V120.21.1333.1333
Published: 2012
Journal Articles

Combining ABL1 Kinase Inhibitor, Imatinib and the Jak Kinase Inhibitor TG101348: A Potential Treatment for Residual BCR-ABL Positive Leukemia Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, M.D., Seiichiro Katagiri, MD, Yuko Tanaka, MD, Kazuma Ohyashiki, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 3737.
https://doi.org/10.1182/blood.V120.21.3737.3737
Published: 2012